Tumor Necrosis Factor Inhibitor Monotherapy Versus Combination Therapy for the Treatment of Psoriatic Arthritis: Combined Analysis of European Biologics Databases.

Thomas, Matthew L; Shaddick, Gavin; Charlton, Rachel; Cavill, Charlotte; Holland, Richard; Iannone, Florenzo; Lapadula, Giovanni; Lopriore, Simona; Závada, Jakub; Uher, Michal; Pavelka, Karel; Szczuková, Lenka; Sidiropoulos, Prodromos; Flouri, Irini; Drosos, Alexandros; Möller, Burkhard; Nissen, Michael J; Müller, Rüdiger B; Scherer, Almut; McHugh, Neil; ... (2021). Tumor Necrosis Factor Inhibitor Monotherapy Versus Combination Therapy for the Treatment of Psoriatic Arthritis: Combined Analysis of European Biologics Databases. The journal of rheumatology, 48(1), pp. 48-57. The Journal of Rheumatology Publishing Company Limited 10.3899/jrheum.190815

Text Tumor_Necrosis_Factor_Inhibitor_Monotherapy_M_ller_2020.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (504kB) | Request a copy

OBJECTIVE

To investigate whether tumor necrosis factor inhibitor (TNFi) combination therapy with conventional synthetic disease-modifying antirheumatic drugs (csDMARD) is more effective for psoriatic arthritis (PsA) and/or improves TNFi drug survival compared to TNFi monotherapy.

METHODS

Five PsA biologics cohorts were investigated between 2000 and 2015: the ATTRA registry (Czech Republic); the Swiss Clinical Quality Management PsA registry; the Hellenic Registry of Biologics Therapies (Greece); the University of Bari PsA biologics database (Italy); and the Bath PsA cohort (UK). Drug persistence was analyzed using Kaplan-Meier and equality of survival using log-rank tests. Comparative effectiveness was investigated using logistic regression with propensity scores. Separate analyses were performed on (1) the combined Italian/Swiss cohorts for change in rate of Disease Activity Score in 28 joints (DAS28); and (2) the combined Italian, Swiss, and Bath cohorts for change in rate of Health Assessment Questionnaire (HAQ).

RESULTS

In total, 2294 patients were eligible for the drug survival analysis. In the Swiss (P = 0.002), Greek (P = 0.021), and Bath (P = 0.014) databases, patients starting TNFi in combination with methotrexate had longer drug survival compared to monotherapy, while in Italy the monotherapy group persisted longer (P = 0.030). In eligible patients from the combined Italian/Swiss dataset (n = 1056), there was no significant difference between treatment arms in rate of change of DAS28. Similarly, when also including the Bath cohort (n = 1205), there was no significant difference in rate of change of HAQ.

CONCLUSION

Combination therapy of a TNFi with a csDMARD does not appear to affect improvement of disease activity or HAQ versus TNFi monotherapy, but it may improve TNFi drug survival.

Interest & Impact

Downloads

1 since deposited on 23 Dec 2020
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item